<SEC-DOCUMENT>0001193125-24-127437.txt : 20240501
<SEC-HEADER>0001193125-24-127437.hdr.sgml : 20240501
<ACCEPTANCE-DATETIME>20240501160611
ACCESSION NUMBER:		0001193125-24-127437
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240501
DATE AS OF CHANGE:		20240501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276774
		FILM NUMBER:		24902954

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d830270d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774</FONT></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
February&nbsp;5, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g830270g0430102438644.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February&nbsp;5, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> excluding the quote of Dr.&nbsp;John Friend contained in Exhibit 99.1 thereto, furnished to the Securities and Exchange Commission on May 1, 2024 (the &#147;May 1, 2024 Form <FONT
STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have attached the May 1, 2024 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except
in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this
prospectus supplement, you should rely on the information in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market
(&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On April&nbsp;30, 2024, the last reported sale price of the ADSs on Nasdaq was $0.3348 per ADS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk
Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently
filed reports and, if any, in any applicable prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is May 1, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of May, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9745;&#8195;&#8195;&#8195; Form
<FONT STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May 1, 2024, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled, &#147;Kazia Reports Successful
Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients.&#148; A copy of this release is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr.&nbsp;John
Friend contained in Exhibit 99.1, into the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224</FONT> and
<FONT STYLE="white-space:nowrap">333-276091).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated May 1, 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited </B>(Registrant)<B></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: 1 May 2024</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g830270g0430102438644.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1&nbsp;May 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, May&nbsp;1, 2024 &#150; Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the
Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consisting of the trial&#146;s lead investigators, independent medical monitor, and key members from Kazia Therapeutics, the SRT has reviewed all preliminary <FONT
STYLE="white-space:nowrap">(non-final)</FONT> safety and pharmacokinetic (PK) data, and unanimously agreed that the maximal tolerated dose (MTD) has been reached at 500mg twice a day (BID). Under the condition that continuous monotherapy
administration will be used in future clinical trials, 400mg BID was identified as the starting recommended phase 2 dose (RP2D). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A total of 26 patients
received EVT801 across six dosing cohorts ranging from 50mg daily to 500mg BID. In general, EVT801 was tolerated across all doses with the majority of toxicities being mild to moderate and transient in nature. Eleven different cancer types (ex.
colon, renal cell, pancreatic) were enrolled in the study, with advanced ovarian cancer being the most prevalent (11 patients). These 11 patients had an average age of 67 years (range: <FONT STYLE="white-space:nowrap">56-76)</FONT> and a median time
from diagnosis of nine years. <FONT STYLE="white-space:nowrap">Forty-six</FONT> percent (46%) of the ovarian cancer patients had stable disease or better for at least three cycles of EVT801 therapy.&#8195; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EVT801 is a highly selective small molecule VEGFR3 tyrosine kinase inhibitor targeting tumour angiogenesis. Unlike traditional angiokinase inhibitors, we
believe based on preclinical data that EVT801 has favorable immune activity (reduces immunosuppressive cells and no impact on CD3+ <FONT STYLE="white-space:nowrap">T-cells</FONT> proliferation) and stabilizes tumor blood vessels, minimizing hypoxia
and therefore decreases the potential for metastatic spread. The Phase 1 EVT801 monotherapy dose-finding trial targets patients with histologically confirmed advanced or metastatic solid tumours that are unresponsive to standard treatment, or for
whom no standard treatment is available or appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics CEO, Dr.&nbsp;John Friend said: &#147;We are extremely pleased that the
primary and secondary end points of stage 1 of the Phase 1 clinical trial have been met. The signals of clinical activity, especially in patients with advanced ovarian cancer are highly encouraging as we continue to progress the clinical development
program for EVT801 as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> VEGFR3 inhibitor. With a median survival time of less than 4 years, there is a large unmet need for new therapies in
patients with high-grade serous ovarian cancer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 1, open label study is designed to assess the safety, tolerability, and PK of EVT801 in
patients with advanced or metastatic solid tumors unresponsive to standard treatment, or for whom no standard treatment is available or appropriate. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Primary Objective:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;To evaluate the safety and tolerability of EVT801 in subjects with advanced or
metastatic solid tumours.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;To determine the MTD and / or a&nbsp;RP2D of EVT801 when administered daily to subjects with
advanced or metastatic solid tumours.</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g830270g0430102438644.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Secondary Objectives:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;To characterise the PK of EVT801 following administration in an oral capsule
formulation.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;To identify
active metabolites of EVT801 in plasma.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;To determine preliminary <FONT STYLE="white-space:nowrap">anti-tumour</FONT> activity of EVT801
via assessment of overall response rate.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We look forward to sharing the final stage 1 data and next development steps at an upcoming scientific conference in the
second half of 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms
of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in
glioblastoma, GBM AGILE, is ongoing, with final data expected in 1H2024. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and FTD for glioblastoma by the FDA in August 2020. Paxalisib was
also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug
Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. Stage one of the Phase I study has been completed and preliminary data is anticipated in CY2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any
statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of EVT801 as a VEGFR3 inhibitor
and the potential market opportunity for EVT801. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals,
and related to the impact of global economic conditions. These and other risks </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g830270g0430102438644.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States
Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place
undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for release by
Dr John Friend, CEO. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g830270g0430102438644.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g830270g0430102438644.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ -(# 2(  A$! Q$!_\0
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MN;\+3ZE,UP+PRM&,;3+G.?;-=)652'LY<IM0JJM!32M<**;(2L;,.H!->-^
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MV.AYZ&EN=/-S=PS-,0L3!PH49R/?K@]ZN44^>0.E!BT4E%0:"T4E% "T4E%
'"T4E% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
